PHIA Koninklijke Philips N.V.

Philips showcases comprehensive cardiology portfolio designed to increase physician confidence and efficiency in diagnosing and treating cardiac disease at ACC/WCC 2023

Philips showcases comprehensive cardiology portfolio designed to increase physician confidence and efficiency in diagnosing and treating cardiac disease at ACC/WCC 2023

March 2, 2023

  • Philips Ultrasound Compact System 5500 CV adds to Philips’ cardiology portfolio bringing diagnostic quality cardiac imaging to the patient bedside 
  • Clinical evidence presented by leading clinical partners shows how utilization of Philips cardiology solutions improves patient care

Amsterdam, the Netherlands (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing enhancements to its cardiology portfolio at the Annual event (ACC.23/WCC, March 4 – 6, New Orleans, USA). Philips’ cardiology portfolio addresses ever-increasing demand for cost-effective diagnosis, treatment, monitoring, and management of patients with heart conditions such as coronary artery disease, structural heart disease, arrhythmia, and heart failure.

Highlighted introductions to the portfolio include the company’s latest compact portable ultrasound platform – , its spectral-detector based CT scanner, , and 3D ICE.

Evidence-based cardiology innovation

In line with Philips’ commitment to supporting its innovations with clinical evidence, three of the company’s clinical partners will present the results of clinical studies at ACC.23/WCC that could help inform clinical guidelines.

  • Dr. Eric Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center (Boston, MA, USA) will present the results of a high-quality real-world evidence study of data for over a million U.S. Medicare patients to evaluate trends in the use of, and outcomes associated with, intravascular imaging (IVI) during percutaneous coronary intervention (PCI) procedures. Philips is a leader in IVI with its .
  • Dr. Mohamad Alkhouli, Professor of Medicine at Mayo Clinic School of Medicine (Rochester, MN, USA) will present a study on the real-world 3D ICE.
  • Dr. Sean Pokorney, Assistant Professor of Medicine and Member of the Duke Clinical Research Institute at Duke University School of Medicine (Durham, NC, USA) will examine the (CIEDs), for which Philips is the market leader in lead management devices.

All three clinical studies are part of more than 110 ongoing clinical studies that support Philips image-guided therapy solutions with clinical evidence.

Other highlighted innovations from its cardiology portfolio that Philips is showcasing at ACC.23/WCC are the company’s advanced image-guided therapy platform ; interventional workspace; providing fast, easy access to ECGs from almost anywhere in the medical facility; and ambulatory cardiac monitoring solution. 

For a more complete overview with in-depth information of the Philips solutions showcased at ACC.23/WCC please see our .

To connect with experts and learn more about Philips cardiology solutions, stop by Philips booth #338. The clinical study presentation by Dr. Mohamad Alkhouli will take place on March 4, 2023, 1:45 PM - 1:55 PM (CST) and the presentation by Dr. Sean Pokorney on March 6, 2023, 9:45 AM - 10:30 AM (CST). The presentation by Dr. Eric Secemsky is in digital-only format and can be accessed through the ACC.23/WCC by registered users.



For further information, please contact:

Joost Maltha 

Philips Global Press Office 

Tel: +31 6 10 55 8116  

Email: 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments



EN
02/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch